Hepatitis B Topics HBV Treatment
Entecavir (Baraclude) Less Effective for Patients with Multidrug-Resistant Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 04 October 2011 00:00
- Written by Liz Highleyman
The nucleoside analog antiviral drug entecavir (Baraclude) was minimally effective against hepatitis B virus (HBV) that had already developed resistance to lamivudine (Epivir-HBV) and adefovir (Hepsera), researchers reported in the October 2011 Journal of Viral Hepatitis. Patient who achieved good early response, however, can do well if they stay on entecavir.
Long-Term Efficacy of Entecavir for People with Hepatitis B
- Details
- Category: HBV Treatment
- Published on Wednesday, 17 August 2011 00:00
- Written by James Learned
Long-term entecavir (Baraclude) monotherapy leads to a virological response in a large majority of nucleoside/nucleotide analog-naive patients, even those who still have detectable HBV DNA at 48 weeks.
Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by James Learned
In a head-to-head comparison, entecavir (Baraclude) demonstrated superior virological efficacy compared to adefovir (Hepsera) in hepatitis B patients with decompensated liver disease.
Early HBeAg Decrease Predicts Response to Entecavir (Baraclude) for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 August 2011 00:00
- Written by Liz Highleyman
Decreases in hepatitis B "e" antigen (HBeAg) during the first 6 months of treatment with entecavir (Baraclude) are a better indicator than hepatitis B virus (HBV) DNA levels of which patients will go on to achieve HBeAg seroconversion, according to a recent Chinese study.
HBV Antivirals, Viral Breakthrough, and Drug Resistance
- Details
- Category: HBV Treatment
- Published on Tuesday, 12 July 2011 00:00
- Written by James Learned
Virological breakthrough is common among people taking nucleoside/nucleotide analogs for HBV, but nearly 40% are unrelated to drug resistance.
As described in the June 2011 issue of Hepatology by Chanunta Hongthanakornand colleagues from the University of Michigan Health System, medication adherence is likely to be lower in real-world clinical practice than in clinical trials. Differentiating between virological breakthroughs caused by drug resistance and those due to poor adherence can help clinicians provide better care and treatment for people with hepatitis.
Web Design and Development by